Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ArQule
Norwood, Massachusetts, United Statesarqule.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ArQule’s lead candidate ARQ531 is a novel oral BTK inhibitor showing promise in phase 2 dose expansion studies for difficult-to-treat B-cell malignancies. Miransertib is advancing in registrational trials targeting rare overgrowth syndromes. Derazantinib has orphan drug designation for intrahepatic cholangiocarcinoma. The pipeline reflects precision medicine approaches targeting biomarker-defined patient populations.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecule therapeutics
- Industry
- Biotech
02
Partnerships
Partnership with Merck post-acquisition to advance oncology pipelineCollaboration on derazantinib development
Beyond the preview
Go deeper on ArQule.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArQule.